home / stock / ctrv / ctrv news

CTRV News and Press, ContraVir Pharmaceuticals Inc. From 06/07/19

Stock Information
Company Name: ContraVir Pharmaceuticals Inc.
Stock Symbol: CTRV
Market: NASDAQ
Website: contravir.com
Menu
CTRV CTRV Quote CTRV Short CTRV News CTRV Articles CTRV Message Board
Get CTRV Alerts

News, Short Squeeze, Breakout and More Instantly...
CTRV - BYND, ZM, JAGX and DOMO among notable midday movers

Gainers:  Stewardship Financial (NASDAQ: SSFN ) +73% . Beyond Meat (NASDAQ: BYND ) +36% . La Jolla Pharmaceutical (NASDAQ: LJPC ) +25% . ReWalk Robotics (NASDAQ: RWLK ) +26% . Neptune Wellness Solutions (NASDAQ: NEPT ) +21% . Zoom Video Communications (NASDAQ: ZM ) +21% . Horizo...
CTRV - CIEN, SFIX, HOME and CLDR among midday movers

Gainers:  La Jolla Pharmaceutical (NASDAQ: LJPC ) +87% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +74% . Ciena Corporation (NYSE: CIEN ) +24% . Cidara Therapeutics (NASDAQ: CDTX ) +21% . Dynatronics Corporation (NASDAQ: DYNT ) +16% . Stitch Fix (NASDAQ: SFIX ) +15% . Eloxx Phar...

CTRV - CIEN, CTRV among premarket gainers

ContraVir Pharmaceuticals (NASDAQ: CTRV ) +123%  on encouraging CRV431 data . More news on: ContraVir Pharmaceuticals, Inc., Stitch Fix, Inc., Ciena Corporation, Stocks on the move, Read more ...

CTRV - ContraVir up 139% premarket on encouraging CRV431 data

Thinly traded nano cap ContraVir Pharmaceuticals (NASDAQ: CTRV ) is up  139%  premarket on increased volume in reaction to positive preclinical data on NASH candidate CRV431. More news on: ContraVir Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Healthcare stocks news,...
CTRV - ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis

EDISON, N.J., June 06, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral i...

CTRV - ContraVir down 8% premarket on 1:70 reverse stock split

Aimed at regaining compliance with Nasdaq listing requirements, ContraVir Pharmaceuticals (NASDAQ: CTRV ) has announced a 1:70 reverse split of its common stock, effective May 31. More news on: ContraVir Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read mor...

CTRV - ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision

EDISON, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, a...
CTRV - ContraVir Pharmaceuticals to Present at the 2019 ThinkEquity Conference

EDISON, N.J., April 29, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, today...

CTRV - ContraVir prices equity offering; shares down 51% premarket

Nano cap ContraVir Pharmaceuticals (NASDAQ: CTRV ) slumps  51%  premarket on modest volume in reaction to its  public offering of Class A and Class B Units. More news on: ContraVir Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

CTRV - ContraVir Pharmaceuticals, Inc. Announces Pricing of $2.14 Million Public Offering

EDISON, N.J., April 25, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (“ContraVir,” the “Company,” “we,” “our” or “us”) (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs...
Previous 10 Next 10